OCGN
NASDAQ · Biotechnology
Ocugen Inc
$1.88
+0.08 (+4.44%)
Open$1.80
Previous Close$1.80
Day High$1.90
Day Low$1.80
52W High$2.73
52W Low$0.64
Volume—
Avg Volume9.39M
Market Cap487.46M
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+1,494.1% upside
Current
$1.88
$1.88
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.81M | 214.85M | 205.76M |
| Net Income | -58,599,314 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,537.4% | -7.8% | -9.5% |
| EBITDA | -52,869,027 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | — | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |